PIK3CA I391M

CI-VAR-00001997Explore in graph →NP_006209.2:p.Ile391MetNM_006218.3:c.1173A>GClinVar 135038 CIViC 1235 rs2230461

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HER2-Positive Breast Carcinoma2
PIK3CA I391M	Trastuzumab	Predictive	D	Does Not Support Resistance	2	accepted	EID8663 As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was ass… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC	civic
PIK3CA I391M	Trastuzumab Emtansine	Predictive	D	Does Not Support Resistance	3	accepted	EID2867 As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associate… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
135038	Benign	reviewed by expert panel	3	Cowden syndrome; Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes; Cowden syndrome 5; Neoplasm	germline/somatic	12	Feb 11, 2022	clinvar